Skip to main content

Table 3 Efficacy of second line gemcitabine and nab-paclitaxel

From: Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Median time to treatment failure, weeks 12.0 (2.0–36.0)
Median overall survival, weeks 23.0 (2.1–85.4)
Response by RECIST, n (%)
 Partial response 5 (17.9)
 Stable disease 8 (28.6)
 Progressive disease 12 (42.8)
 Inevaluable 3 (10.7)
Serologic response, n (%)a
 CA 19-9 13 (46.4)
 CEA 11 (39.3)
  1. a>30 % decrease from pre-treatment baseline